Discovery and development of melanin-concentrating hormone receptor 1 antagonists for the treatment of obesity

Expert Opinion on Drug Discovery

Volumn 2, Issue 10, 2007, Pages 1301-1327

  Rokosz, Laura L ^a  

^a PHARMACOPEIA INC   (United States)

Author keywords

GPCR; MCH; MCH1; MCH2; Melanin concentrating hormone; Metabolic disease; Neuropeptide; Obesity; Orexigenic

Indexed keywords

AMG 076; ANTIOBESITY AGENT; BENZIMIDAZOLE DERIVATIVE; BENZOTRIAZOLE DERIVATIVE; DIAMINE DERIVATIVE; GW 803430; GW 856464; HORMONE RECEPTOR BLOCKING AGENT; HYPOTHALAMUS HORMONE; INDAZOLE DERIVATIVE; INDOLE DERIVATIVE; JP 226269; MELANIN CONCENTRATING HORMONE; MELANIN CONCENTRATING HORMONE RECEPTOR 1; MELANIN CONCENTRATING HORMONE RECEPTOR 1 BLOCKING AGENT; MELANIN CONCENTRATING HORMONE RECEPTOR 2; N (6 DIMETHYLAMINOMETHYL 5,6,7,8 TETRAHYDRO 2 NAPHTHYL) 4' FLUORO 1,1' BIPHENYL 4 CARBOXAMIDE; NEUROPEPTIDE RECEPTOR; NGD 4715; PEPTIDE HORMONE RECEPTOR BLOCKING AGENT; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; PLACEBO; PYRIMIDINONE DERIVATIVE; QUINAZOLINE DERIVATIVE; QUINOLINE DERIVATIVE; SB 568849; SNAP 7941; SNAP 94847; T 0910792; T 71; UNCLASSIFIED DRUG; UNINDEXED DRUG;

APPETITE; AREA UNDER THE CURVE; CLINICAL TRIAL; DISEASE MODEL; DOG; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG SELECTIVITY; DRUG STRUCTURE; FOOD INTAKE; HIGH THROUGHPUT SCREENING; HUMAN; INHIBITION KINETICS; NONHUMAN; OBESITY; PRIORITY JOURNAL; RECEPTOR BINDING; REVIEW; WEIGHT REDUCTION;

EID: 35348868605     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460441.2.10.1301     Document Type: Review

References (100)

1. KAWAUCHI H, KAWAZOE I, TSUBOKAWA M et al: Characterization of melanin-concentrating hormone in chum salmon pituitaries. Nature (1983) 305(5932):321-323.
2. SHIMADA M, TRITOS NA, LOWELL BB et al.: Mice lacking melanin-concentrating hormone are hypophagic and lean. Nature (1998) 396(6712):670-674.
3. LUDWIG DS, TRITOS NA, MASTAITIS JW et al.: Melanin-concentrating hormone overexpression in transgenic mice leads to obesity and insulin resistance. J. Clin. Invest. (2001) 107(3):379-386.
4. SUPLY T, DELLA ZUANA O, AUDINOT V et al.: SLC-1 receptor mediates effect of melanin-concentrating hormone on feeding behavior in rat: a structure-activity study. J. Pharmacol Exp. Ther. (2001) 299(1):137-146.
5. DELLA-ZUANA O, PRESSE F, ORTOLA C et al.: Acute and chronic administration of melanin-concentrating hormone enhances food intake and body weight in Wistar and Sprague-Dawley rats. Int. J. Obes. Relat. Metab. Disord. (2002) 26(10):1289-1295.
6. GOMORI A, ISHIHARA A, ITO M et al.: Chronic intracerebroventricular infusion of MCH causes obesity in mice. Am. J. Physiol. Endocrinol. Metab. (2003) 284(3 Part 1):E583-E588.
7. BACHNER D, KREIENKAMP H, WEISE C et al.: Identification of melanin concentrating hormone (MCH) as the natural ligand for the orphan somatostatin-like receptor 1 (SLC-1). FEBS Lett. (1999) 457(3):522-524.
8. CHAMBERS J, AMES RS, BERGSMA D et al.: Melanin-concentrating hormone is the cognate ligand for the orphan G-protein-coupled receptor SLC-1. Nature (1999) 400(6741):261-264.
9. SAITO Y, NOTHACKER H-P, WANG Z et al.: Molecular characterization of the melanin-concentrating-hormone receptor. Nature (1999) 400(6741):265-269.
10. CHEN Y, HU C, HSU C-K et al.: Targeted disruption of the melanin-concentrating hormone receptor-1 results in hyperphagia and resistance to diet-induced obesity. Endocrinology (2002) 143(7):2469-2477.
11. ASTRAND A, BOHLOOLY YM, LARSDOTTER S et al.: Mice lacking melanin-concentrating hormone receptor 1 demonstrate increased heart rate associated with altered autonomic activity. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2004) 287(4):R749-R758.
12. MARSH DJ, WEINGARTH DT, NOVI DE et al.: Melanin-concentrating hormone 1 receptor-deficient mice are lean, hyperactive, and hyperphagic and have altered metabolism. Proc. Natl. Acad. Sci. USA (2002) 99(5):3240-3245.
13. HAWES BE, KIL E, GREEN B et al.: The melanin-concentrating hormone receptor couples to multiple G proteins to activate diverse intracellular signaling pathways. Endocrinology (2000) 141(12):4524-4532.
14. HERVIEU GJ, CLUDERAY JE, HARRISON D et al.: The distribution of the mRNA and protein products of the melanin-concentrating hormone (MCH) receptor gene, SLC-1, in the central nervous system of the rat. Eur. J. Neurosci. (2000) 12(4):1194-1216.
15. BRADLEY RL, KOKKOTOU EG, MARATOS-FLIER E et al.: Melanin-concentrating hormone regulates leptin synthesis and secretion in rat adipocytes. Diabetes (2000) 49(7):1073-1077.
16. BRADLEY RL, MANSFIELD JPR, MARATOS-FLIER E et al.: Melanin-concentrating hormone activates signaling pathways in 3T3-l1 adipocytes. Am. J. Physiol. Endocrinol. Metab. (2002) 283(3 Part 1):E584-E592.
17. BOHLOOLY YM, MAHLAPUU M, ANDERSEN H et al.: Osteoporosis in MCHR1-deficient mice. Biochem. Biophys. Res. Commun. (2004) 318(4):964-969.
18. VERLAET M, ADAMANTIDIS A, COUMANS B et al.: Human immune cells express ppMCH mRNA and functional MCHR1 receptor. FEBS Lett. (2002) 527(1-3):205-210.
19. AN S, CUTLER G, ZHAO JJ et al.: Identification and characterization of a melanin-concentrating hormone receptor. Proc. Natl. Acad. Sci. USA (2001) 98(13):7576-7581.
20. SAILER AW, SANO H, ZENG Z et al.: Identification and characterization of a second melanin-concentrating hormone receptor, MCH-2R. Proc. Natl. Acad. Sci. USA (2001) 98(13):7564-7569.
21. HILL J, DUCKWORTH M, MURDOCK P et al.: Molecular cloning and functional characterization of MCH2, a novel human MCH receptor. J. Biol. Chem. (2001) 276(23):20125-20129.
22. WANG S, BEHAN J, O'NEILL K et al.: Identification and pharmacological characterization of a novel human melanin-concentrating hormone receptor, MCH-R2. J. Biol. Chem (2001) 276(37):34664-34670.
23. ROKOSZ LL, HOBBS DW. Biological examination of melanin concentrating hormone receptor 1: multi-tasking from the hypothalamus. Drug News Perspect. (2006) 19(5):273-286.
24. BEDNAREK MA, TAN C, HRENIUK DL et al.: Synthesis and biological evaluation in vitro of a selective, high potency peptide agonist of human melanin-concentrating hormone action at human melanin-concentrating hormone receptor 1. J. Biol. Chem. (2002) 277(16):13821-13826.
25. BEDNAREK MA, HRENIUK DL, TAN C et al.: Synthesis and biological evaluation in vitro of selective, high affinity peptide antagonists of human melanin-concentrating hormone action at human melanin-concentrating hormone receptor 1. Biochemistry (2002) 41(20):6383-6390.
26. HERTZOG DL, AL-BARAZANJI KA, BIGHAM EC et al.: The discovery and optimization of pyrimidinone-containing MCH R1 antagonists. Bioorg. Med Chem. Lett. (2006) 16(18):4723-4727.
27. MCBRIAR MD, GUZIK H, SHAPIRO S et al.: Bicyclo[3.1.0]hexyl urea melanin concentrating hormone (MCH) receptor-1 antagonists: impacting hERG liability via aryl modifications. Bioorg. Med. Chem. Lett. (2006) 16(16):4262-4265.
28. JUDD AS, SOUERS AJ, WODKA D et al.: Identification of diamino chromone-2-carboxamides as MCHR1 antagonists with minimal hERG channel activity. Bioorg. Med. Chem. Lett. (2007) 17(8):2365-2371.
29. LYNCH JK, FREEMAN JC, JUDD AS et al.: Optimization of chromone-2-carboxamide melanin concentrating hormone receptor 1 antagonists: assessment of potency, efficacy, and cardiovascular safety. J. Med Chem. (2006) 49(22):6569-6584.
30. KYM PR, SOUERS AJ, CAMPBELL TJ et al.: Screening for cardiovascular safety: a structure-activity approach for guiding lead selection of melanin concentrating hormone receptor 1 antagonists. J. Med. Chem. (2006) 49(7):2339-2352.
31. MENDEZ-ANDINO JL, COLSON A-O, MEYERS KM et al.: The efficacy and cardiac evaluation of aminomethyl tetrahydronaphthalene ketopiperazines: a novel class of potent MCH-R1 antagonists. Bioorg. Med. Chem. (2007) 15(5):2092-2105.
32. WALTERS WP, NAMCHUK M: Designing screens: how to make your hits a hit. Nat. Rev. Drug Discov. (2003) 2(4)259-266.
33. BLEICHER KH, BOHM H-J, MULLER K et al.: Hit and lead generation: beyond high-throughput screening. Nat. Rev. Drug Discov. (2003) 2(5):369-378.
34. COLLINS CA, KYM PR. Prospects for obesity treatment: MCH receptor antagonists. Curr. Opin. Investig. Drugs (2003) 4(4):386-394.
35. BROWNING A: Recent developments in the discovery of melanin-concentrating hormone antagonists: novel antiobesity agents. Expert Opin. Ther. Patents (2004) 14(3):313-325.
36. DYKE HJ, RAY NC: Recent developments in the discovery of MCH-1R antagonists for the treatment of obesity - an update. Expert Opin. Ther. Patents (2005) 15(10):1303-1313.
37. KOWALSKI TJ, MCBRIAR MD: Therapeutic potential of melanin-concentrating hormone-1 receptor antagonists for the treatment of obesity. Expert Opin. Investig. Drugs (2004) 13(9):1113-1122.
38. MCBRIAR MD, KOWALSKI TJ: Melanin-concentrating hormone as a therapeutic target. Ann. Rep. Med. Chem. (2005) 40:119-133.
39. TAKEKAWA S, ASAMI A, ISHIHARA Y et al.: T-226296: a novel, orally active and selective melanin-concentrating hormone receptor antagonist. Eur. J. Pharmacol. (2002) 438(3):129-135.
40. BOROWSKY B, DURKIN MM, OGOZALEK K et al.: Antidepressant, anxiotytic and anorectic effects of a melanin-concentrating hormone-1 receptor antagonist. Nat. Med. (2002) 8(8):825-830.
41. BASSO AM, BRATCHER NA, GALLAGHER KB et al.: Lack of efficacy of melanin-concentrating hormone-1 receptor antagonists in models of depression and anxiety. Eur J. Pharmacol. (2006) 540(1-3):115-120.
42. DAVID DJ, KLEMENHAGEN KC, HOLICK KA et al.: Efficacy of the MCHR1 antagonist n-[3-(1-{[4-(3,4-difluorophenoxy)phenyl]methyl}- (4-piperidyl))-4-methylphenyl]-2-methylpropanamide (SNAP 94847) in mouse models of anxiety and depression following acute and chronic administration is independent of hippocampal neurogenesis. J. Pharmacol. Exp. Ther. (2007) 321(1):237-248.
43. WITTY DR, BATESON JH, HERVIEU GJ et al.: SAR of biphenyl carboxamide ligands of the human melanin-concentrating hormone receptor 1 (MCH RI): discovery of antagonist SB-568849. Bioorg. Med. Chem. Lett. (2006) 16(18):4865-4871.
44. HALFORD JCG, HARROLD JA, LAWTON CL et al.: Serotonin (5-HT) drugs: effects on appetite expression and use for the treatment of obesity. Curr. Drug Targets (2005) 6(2):201-213.
45. WITTY DR, BATESON J, HERVIEU GJ et al.: Discovery of potent and stable conformationally constrained analogues of the MCH R1 antagonist SB-568849. Bioorg. Med. Chem. Lett. (2006) 16(18):4872-4878.
46. TAVARES FX, AL-BARAZANJI KA, BISHOP MJ et al.: 6-(4-Chlorophenyl)-3-substituted-thieno[3,2-d]pyrimidin-4(3h)-one-based melanin-concentrating hormone receptor 1 antagonist. J. Med Chem. (2006) 49(24):7108-7118.
47. TAVARES FX, AL-BARAZANJI KA, BIGHAM EC et al.: Potent, selective, and orally efficacious antagonists of melanin-concentrating hormone receptor 1. J. Med. Chem. (2006) 49(24):7095-7107.
48. CARPENTER AJ, AL-BARAZANJI KA, BARVIAN KK et al.: Novel benzimidazole-based MCH R1 antagonists. Bioorg. Med Chem. Lett. (2006) 16(19):4994-5000.
49. LI L, FAN P, CHEN X et al.: SAR study on a novel series of pyridocarbazole-based melanin concentrating hormone receptor-1 antagonists: discovery of T0910792, a potent, selective and orally bioavailable agent that is efficacious in obesity models. Abstracts of Papers, 231st ACS National Meeting, Atlanta, GA, USA (2006):MED1197.
50. MA V, BANNON AW, BAUMGARTNER J et al.: Solid-phase synthesis and structure-activity relationships of novel biarylethers as melanin-concentrating hormone receptor-1 antagonists. Bioorg. Med Chem. Lett. (2006) 16(19):5066-5072.
51. TEMPEST PA, NIXEY T, MA V et al.: Novel potent tetrazole containing melanin concentrating hormone (MCH) receptor antagonists: multi-component reactions lead the way. Abstracts of Papers, 227th ACS National Meeting, Anaheim, CA, USA (2004):MED1298.
52. SOUERS AJ, WODKA D, GAO J et al.: Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHR1 antagonists. Part 1. Bioorg. Med Chem. Lett. (2004) 14(19):4873-4877.
53. VASUDEVAN A, WODKA D, VERZAL MARY K et al.: Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHR1 antagonists. Part 2. Bioorg. Med. Chem. Lett. (2004) 14(19):4879-4882.
54. SOUERS AJ, WODKA D, GAO J et al.: Synthesis and evaluation of 2-amino-8-alkoxy quinolines as MCHR1 antagonists. Part 3. Bioorg. Med Chem. Lett. (2004) 14(19):4883-4886.
55. VASUDEVAN A, VERZAL MK, WODKA D et al.: Identification of aminopiperidine benzamides as MCHR1 antagonists. Bioorg. Med. Chem. Lett. (2005) 15(14):3412-3416.
56. VASUDEVAN A, SOUERS AJ, FREEMAN JC et al.: Aminopiperidine indazoles as orally efficacious melanin concentrating hormone receptor-1 antagonists. Bioorg. Med. Chem. Lett. (2005) 15(23):5293-5297.
57. SOUERS AJ, GAO J, BRUNE M et al.: Identification of 2-(4-benzyloxyphenyl)-n-[1-(2-pyrrolidin-1-yl-ethyl)-1h-indazol- 6-yl]acetamide, an orally efficacious melanin-concentrating hormone receptor 1 antagonist for the treatment of obesity. J. Med. Chem. (2005) 48(5):1318-1321.
58. SOUERS AJ, GAO J, WODKA D et al.: Synthesis and evaluation of urea-based indazoles as melanin-concentrating hormone receptor 1 antagonists for the treatment of obesity. Bioorg. Med. Chem. Lett. (2005) 15(11):2752-2757.
59. KYM PR, IYENGAR R, SOUERS AJ et al.: Discovery and characterization of aminopiperidinecoumarin melanin concentrating hormone receptor 1 antagonists. J. Med. Chem. (2005) 48(19):5888-5891.
60. BLACKBURN C, LAMARCHE MJ, BROWN J et al.: Identification and characterization of amino-piperidinequinolones and quinazolinones as MCHR1 antagonists. Bioorg. Med. Chem. Lett. (2006) 16(10):2621-2627.
61. IYENGAR RR, LYNCH JK, MULHERN MM et al.: An evaluation of 3,4-methylenedioxy phenyl replacements in the aminopiperidine chromone class of MCHR1 antagonists. Bioorg. Med. Chem. Lett. (2007) 17(4):874-878.
62. GUO T, SHAO Y, QIAN G et al.: Discovery and SAR of biaryl piperidine MCH1 receptor antagonists through solid-phase encoded combinatorial. synthesis. Bioorg. Med. Chem. Lett. (2005) 15(16):3696-3700.
63. GUO T, HUNTER RC, GU H et al.: Discovery and SAR of 4-amino-2-biarylbutylurea MCH 1 receptor antagonists through solid-phase parallel synthesis. Bioorg. Med. Chem. Lett. (2005) 15(16):3691-3695.
64. PALANI A, SHAPIRO S, MCBRIAR MD et al.: Biaryl ureas as potent and orally efficacious melanin concentrating hormone receptor 1 antagonists for the treatment of obesity. J. Med Chem. (2005) 48(15):4746-4749.
65. MCBRIAR MD, GUZIK H, XU R et al.: Discovery of bicycloalkyl urea melanin concentrating hormone receptor antagonists: orally efficacious antiobesity therapeutics. J. Med. Chem. (2005) 48(7):2274-2277.
66. MCBRIAR MD, GUZIK H, SHAPIRO S et al.: Discovery of orally efficacious melanin-concentrating hormone receptor-1 antagonists as antiobesity agents. Synthesis, SAR, and biological evaluation of bicycle[3.1.0] hexyl ureas. J. Med. Chem. (2006) 49(7):2294-2310.
67. XU R, LI S, PARUCHOVA J et al.: Bicyclic[4.1.0]heptanes as phenyl replacements for melanin concentrating hormone receptor antagonists. Bioorg. Med. Chem. (2006) 14(10):3285-3299.
68. KOWALSKI TJ, SPAR BD, WEIG B et al.: Effects of a selective melanin-concentrating hormone 1 receptor antagonist on food intake and energy homeostasis in diet-induced obese mice. Eur. J. Pharmacol. (2006) 535(1-3):182-191.
69. WU W-L, BURNETT DA, SPRING R et al.: Synthesis and structure-activity relationships of piperidine-based melanin-concentrating hormone receptor 1 antagonists. Bioorg. Med Chem. Lett. (2006) 16(14):3668-3673.
70. SASIKUMAR TK, QIANG L, BURNETT DUANE A et al.: Novel aminobenzimidazoles as selective MCH-R1 antagonists for the treatment of metabolic diseases. Bioorg. Med. Chem. Lett. (2006) 16(20):5427-5431.
71. SASIKUMAR TK, QIANG L, WU WL et al.: Tetrahydroisoquinofines as MCH-R1 antagonists. Bioorg. Med. Chem. Lett. (2006) 16(18):4917-4921.
72. GREY J, DYCK B, ROWBOTTOM MARTIN W et al.: Bis(aminopyrrolidine)-derived ureas (APUs) as potent MCH 1 receptor antagonists. Bioorg. Med Chem. Lett. (2005) 15(4):999-1004.
73. ROWBOTTOM MW, VICKERS TD, DYCK B et al.: Synthesis and structure-activity relationships of biarylcarboxamide bis-aminopyrrolidine urea derived small-molecule antagonists of the melanin-concentrating hormone receptor-1 (MCH-R1). Bioorg. Med. Chem. Lett. (2005) 15(14):3439-3445.
74. ROWBOTTOM MW, VICKERS TD, DYCK B et al.: Synthesis and structure-activity relationships of retro bis-aminopyrrolidine urea (rAPU) derived small-molecule antagonists of the melanin-concentrating hormone receptor-1 (MCH-R1). Part 1. Bioorg. Med. Chem. Lett. (2006) 16(17):4450-4457.
75. HUDSON S, KIANKARIMI M, ROWBOTTOM MW et al.: Synthesis and structure-activity relationships of retro bis-aminopyrrolidine urea (rAPU) derived small-molecule antagonists of the melanin-concentrating hormone receptor-1 (MCH-R1). Part 2. Bioorg. Med. Chem. Lett. (2006) 16(18):4922-4930.
76. DYCK B, MARKISON S, ZHAO L et al.: A thienopyridazinone-based melanin-concentrating hormone receptor 1 antagonist with potent in vivo anorectic properties. J. Med Chem. (2006) 49(13):3753-3756.
77. ZHANG M, TAMIYA J, NGUYEN L et al.: Thienopyrimidinone bis-aminopyrrolidine ureas as potent melanin-concentrating hormone receptor-1 (MCH-R1) antagonists. Bioorg. Med. Chem. Lett. (2007) 17(9):2535-2539.
78. DYCK B, ZHAO L, TAMIYA J et al.: Substituted chromones and quinolones as potent melanin-concentrating hormone receptor 1 antagonists. Bioorg. Med Chem. Lett. (2006) 16(16):4237-4242.
79. ROWBOTTOM MW, VICKERS TD, TAMIYA J et al.: Synthesis and structure-activity relationships of spirohydantoin-derived small-molecule antagonists of the melanin-concentrating hormone receptor- 1 (MCH-R1). Bioorg. Med. Chem. Lett. (2007) 17(8):2171-2178.
80. RECEVEUR J-M, BJURLING E, ULVEN T et al.: 4-Acylamino- and 4-ureidobenzamides as melanin-concentrating hormone (MCH) receptor 1 antagonists. Bioorg. Med. Chem. Lett. (2004) 14(20):5075-5080.
81. DOKNIC M, PEKIC S, ZARKOVIC M et al.: Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine. Eur J. Pharmacol. (2002) 147(1):77-84.
82. ULVEN T, FRIMURER TM, RECEVEUR J-M et al.: 6-Acylamino-2-aminoquinolines as potent melanin-concentrating hormone 1 receptor antagonists. Identification, structure-activity relationship, and investigation of binding mode. J. Med. Chem. (2005) 48(18):5684-5697.
83. ULVEN T, LITTLE PB, RECEVEUR J-M et al.: 6-Acylamino-2-amino-4-methylquinolines as potent melanin-concentrating hormone 1 receptor antagonists: structure-activity exploration of eastern and western parts. Bioorg. Med. Chem. Lett. (2006) 16(4):1070-1075.
84. KIM N, MEYERS KM, MENDEZ-ANDINO JL et al.: Identification of substituted 4-aminopiperidines and 3-aminopyrrolidines as potent MCH-R1 antagonists for the treatment of obesity. Bioorg. Med. Chem. Lett. (2006) 16(20):5445-5450.
85. WARSHAKOON NC, SHEVILLE J, BHATT RT et al.: Design and synthesis of substituted quinolines as novel and selective melanin concentrating hormone antagonists as anti-obesity agents. Bioorg. Med. Chem. Lett. (2006) 16(19):5207-5211.
86. MEYERS KM, KIM N, MENDEZ-ANDINO JL et al.: Aminomethyl tetrahydronaphthalene biphenyl carboxamide MCH-R1 antagonists-increasing selectivity over hERG. Bioorg. Med. Chem. Lett. (2007) 17(3):814-818.
87. MEYERS KM, MENDEZ-ANDINO JL, COLSON A-O et al.: Aminomethyl tetrahydronaphthalene ketopiperazine MCH-R1 antagonists-increasing selectivity over hERG. Bioorg. Med. Chem. Lett. (2007) 17(3):819-822.
88. MEYERS KM, MENDEZ-ANDINO J, COLSON A-) et al.: Novel pyrazolopiperazinone- and pyrrolopiperazinone-based MCH-R1 antagonists. Bioorg. Med. Chem. Lett. (2007) 17(3):657-661.
89. JIANG J, LIN P, HOANG M et al.: 4-Aminoquinoline melanin-concentrating hormone 1-receptor (MCH1R) antagonists. Bioorg. Med. Chem. Lett. (2006) 16(20):5275-5279.
90. JIANG J, HOANG M, YOUNG JR et al.: 2-Aminoquinoline metanin-concentrating hormone (MCH)1R antagonists. Bioorg. Med Chem. Lett. (2006) 16(20):5270-5274.
91. HERVIEU G: Melanin-concentrating hormone functions in the nervous system: food intake and stress. Expert Opin. Ther. Targets (2003) 7(4):495-511.
92. ARIENZO R, CLARK DE, CRAMP S et al.: Structure-activity relationships of a novel series of melanin-concentrating hormone (MCH) receptor antagonists. Bioorg. Med. Chem. Lett. (2004) 14(15):4099-4102.
93. ARIENZO R, CRAMP S, DYKE HAZEL J et al.: Quinazoline and benzimidazole MCH-1R antagonists. Bioorg. Med. Chem. Lett. (2007) 17(5):1403-1407.
94. KANUMA K, OMODERA K, NISHIGUCHI M et al.: Discovery of 4-(dimethylamino)quinazolines as potent and selective antagonists for the melanin-concentrating hormone receptor 1. Bioorg. Med. Chem. Lett. (2005) 15(10):2565-2569.
95. KANUMA K, OMODERA K, NISHIGUCHI M et al.: Lead optimization of 4-(dimethylamino)quinazolines, potent and selective antagonists for the melanin-concentrating hormone receptor 1. Bioorg. Med. Chem. Lett. (2005) 15(17):3853-3856.
96. CHAKI S, FUNAKOSHI T, HIROTA-OKUNO S et al.: Anxiolytic- and antidepressant-like profile of ATC0065 and ATC0175: nonpeptidic and orally active melanin-concentrating hormone receptor 1 antagonists. J. Pharmacol. Exp. Ther. (2005) 313(2):831-839.
97. KANUMA K, OMODERA K, NISHIGUCHI M et al.: Identification of 4-amino-2-cyclohexylaminoquinazolines as metabolically stable melanin-concentrating hormone receptor 1 antagonists. Bioorg. Med. Chem. (2006) 14(10):3307-3319.
98. FILMORE D: It's a GPCR world. Mod. Drug Discov. (2004) 7(11):24-26, 28.
99. QU D, LUDWIG DS, GAMMELTOFT S et al.: A role for melanin-concentrating hormone in the central regulation of feeding behavior. Nature (1996) 380(6571):243-247.
100. + channel. A model for bad behavior. J. Med Chem. (2003) 46(11):2017-2022.